Press Releases
- Active Biotech raises SEK 43.4 million in substantially oversubscribed rights issue including exercise of over-allotment option
- Active Biotech’s patent for laquinimod in eye disorders will be granted in the US
- Preclinical data of tasquinimod in myelofibrosis to be presented at ASH 2024
- Active Biotech’s clinical trial of tasquinimod in myelofibrosis approved in Europe
- Active Biotech publishes prospectus